With nearly 30 years’ experience of developing accurate assay solutions for diagnosis, prognosis and monitoring treatment we have proven expertise in our focus areas covers several competences.
We prides ourselves on leading on the way in life science, pushing the boundaries in drug development and clinical diagnostics through international cooperation and the sharing of good practice and expertise.
A DOUBLE-EDGED SWORD
The complement system is described as a double-edged sword. If not properly controlled and regulated, the complement system has the potential to harm the host, and disturbances in the system are an effector in a large variety of disorders.
Gene therapy holds great promise as an effective treatment for these diseases. Over the coming decades, gene therapy treatment may be commonplace for various disorders, such as inherited diseases, cancer, and viral infections.
Much of the focus in developing recent gene therapeutic therapies has been on retinal rare diseases that result from modifications in a single gene. These retinal diseases tend to have clear genomic targets and high unmet needs in patient populations and patients.
Reporter gene cell lines and antigen-specific target cells can be used in biologically relevant MOA-reflective assays to measure the Fc effect of antibodies and other biologics that specifically bind and activates Fc receptors.
When done correctly, e-Health greatly benefits the patient, the physicians, the hospital, and society as a whole and can drastically reduce the use of heavy medication, emergency admissions, surgeries, and other expensive treatments.